Hedge funds are making some adjustments to their tech-investing playbook.

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Goldman Sachs warned there's a risk of a 5% slump in US stocks because ... retreated after President Trump imposed an additional 10% tariff on Chinese goods. Moderna (MRNA) closed down more than -7% ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...

The Dow Jones Industrial Average shed 165.35 points, or 0.37%, closing at 44,546.08. The S&P 500 ticked down 0.01% to ...

Shares of Roku Inc (NASDAQ:ROKU) are up 14.5% in premarket trading, after the streaming giant shared smaller-than-expected losses for the fourth quarter as well as a revenue beat. The company also ...

The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.